Canagliflozin approved by NICE for diabetes

NICE has approved canagliflozin (Invokana) for use in dual and triple therapy and in combination with insulin in type II diabetes.

Canagliflozin (Invokana) prevents glucose reabsorption in the kidneys and increases urinary glucose excretion to lower blood glucose levels
Canagliflozin (Invokana) prevents glucose reabsorption in the kidneys and increases urinary glucose excretion to lower blood glucose levels

Janssen-Cilag launched canagliflozin in March for use as monotherapy or in combination with other hypoglycaemics and/or insulin when the existing regimen, in combination with diet and exercise changes, provides inadequate glycaemic control.

The guidance accepts canagliflozin for use in combination with metformin when sulfonylureas are contraindicated or not tolerated or if the patient is at significant risk of hypoglycaemia or its consequences. The SGLT2 inhibitor is also recommended as an option for combination therapy with insulin, with or without other hypoglycaemics.

In addition, canagliflozin can be used on the NHS in a triple oral therapy regimen with metformin plus either a sulfonylurea or a thiazolidinedione ('glitazone'). This differs from the NICE recommendations for dapagliflozin published in June 2013, where the regulatory body rejected dapagliflozin for use in triple oral regimens.

A fixed-dose combination tablet containing canagliflozin and metformin has been approved in the EU but has not yet been launched in the UK.

NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes (TA315)

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more